Ochre Bio

Many donor livers are too unhealthy or damaged to be transplanted and so go to waste, even though one in six patients die waiting for a new liver. The main reason for discarding a donor liver is that it contains too much fat. At Ochre we develop genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other cardiometabolic diseases. We employ spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develop combination therapies which are tested in donor livers kept alive outside of the body. Our scientific roots can be traced back over 15 years leading liver genomics research, and experience in bringing advanced therapies to market. Privately held, Ochre Bio is situated within the heart of Oxford’s biotech innovation hub. To learn more, please visit www.ochre-bio.com.